The clinical value of cathepsin D and TNF-α in bladder cancer patients

Anticancer Research

Volumn 17, Issue 4 B, 1997, Pages 3087-3090

  Salman, Tarekk ^a   El Ahmady, Omar ^a,d   El Shafee, Mostafa ^a   Omar, Sherif ^b   Salman, Ibrahim ^c  

^a AL AZHAR UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c MENOUFIA UNIVERSITY   (Egypt)

^d Al Azhar University   (Egypt)

Author keywords

Bilharziasis; Bladder cancer; Cathepsin D; TNF

Indexed keywords

CATHEPSIN D; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; BLADDER CANCER; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNORADIOMETRIC ASSAY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SCHISTOSOMIASIS; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; CATHEPSIN D; CYTOSOL; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHISTOSOMIASIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA; URINARY BLADDER NEOPLASMS;

EID: 0030841630     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Mokhtar N: Female genital system tumors. In: Cancer pathology registry 1985-1990, National Cancer Institute, Cairo University, P.45, 1991.
2. El-Sebai I: Bladder cancer, Vol. 1, general review. CRC Press Inc Boca Raton Florida P.18, 1983.
3. Goldfarb RH: Proteolytic enzymes in tumor invasion and degradation of host exracellular matrices. In: Honn KV, Powers WE and Sloane BF (eds.), Mechanisms of cancer metastasis. Martinus Nijhoff Publishing, Boston, P.341, 1986.
4. Matrisian LY, Bowden GT, Krieg P, Furstenberger G, Briand JP, Leroy P and Breathnach R: The mRNA coding for the secreted protease transin is expressed more abundantly in malignant than in benign tumors. Proc Natl Acad Sci USA 83: 9413, 1986.
5. Owen-Schaub LB, Gutterman JN and Grimm E: Synergy of tumor necrosis factor and interleukin-2 in the activation of human cytotoxic lymphocytes. Cancer Res 48: 788, 1986.
6. Tracey KJ, Fon GY, Hesse DG, Manogue KR, Lee AT, KUO GC, Lowry SF and Cerami A: Anticachectin TNF monoclonal antibodies prevent septic shock during bacterimia. Nature 330: 662, 1987.
7. Predine J, Spyratos F and Prudhomme JF: Radioimmunoassay of p 52 in breast cancer, benign tumors and normal breast tissues: correlation with prognosis and adjuvant hormone therapy. Cancer 69: 2116, 1992.
8. Bradford, MM (1976): A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72: 255.
9. El-Bolkainy MN; Mokhtar NM; Ghoneim MA and Hussein MH (1981): The impact of schistosomiasis on the pathology of bladder cancer. Cancer 48: 2643.
10. Pohl AL (1990): Tumor markers: potential limits of their application. Egyp J Tumor Marker Ocol 1: 7.
11. Vignon F, Capony F, Chambon M, Freiss G, Garcia M and Rochefort H (1986): Autocrine growth stimulation of the MCF 7 breast cancer cells by the estrogen-regulated 52 K proteins. Endocrinology 118(4): 1537.
12. Briozzo P, Morisset M, Capony F, Rouggeot C and Rochefort H (1988) In vitro degradation of extracellular matrix with Mr 52.000 cathepsin D secreted by breast cancer cells. Cancer Res 48: 3688.
13. Rochefort H: Cathepsin D in breast cancer. Breast Cancer Res Treat 16: 3, 1990.
14. Liotta L: Gene products which may play a role in cancer invasion and metastasis. Breast Cancer Res Treat 11: 113, 1988.
15. Thorpe S, Rochefort H, Garcia M, Gilles F, Christensen IBJ, Khalaf S, Paolucci F, Pau B, Rasmussen B and Rose C: Association between high concentrations of Mr 52.000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49: 6008, 1989.
16. Brouillet JP, Spyratos F, Hacene K, Fauque J, Freiss G, Dupont F, Maudelone T and Rochefort H: Immunoradiometric assay of procathepsin D in breast cancer cytosol: relative prognostic value versus total cathepsin D. Eur J Cancer. 29 A(9): 1248, 1993.
17. Reid WA, Valler MJ and Kay J: Immunolocalisation of cathepsin D in normal and neoplastic human tissues. J Clin Pathol 39: 1323, 1986.
18. Capony F, Rougeot C, Montcourrier P, Cavailles V, Salazar G and Rochefort H: Increased secretion, altered processing and glycosylation of procathepsin D in human mammary cancer cells. Cancer Res 49: 3904, 1989.
19. Namer M, Etienne M and Fontana X: Prognostic value of total cathepsin D in breast cancer. Breast Cancer Res Treat 14: 135, 1989.
20. Khalifa A, Eissa S, Emam M, Said H, Ziada K, Khalil F, Boshnak H, Ismail S and Helal TH: Evaluation of some recent prognostic factors in breast cancer.(Abstract) 3 rd. International Conference of the Mediteranian Society of Tumor Marker Oncology (MESTMO) 26-29 October, 1994, Athens, Greece, 1994.
21. Marsigliante S, Biscozzo L, Correale M, Paradiso A, Leo G, Abbate I, Dragone CD and Storelli C: Immunoradiometric detection of PS2 and total cathepsin D in primary breast cancer biopsies:their correlation with steroid receptors. Br J Cancer 69(3): 550, 1994.
22. Scorilas A, Yotis J, Gouriotis D, Kerampoulos A, Ampela K, Trangas T and Talieri M: Cathepsin D and c-erb-B2 have an additive prognostic value for breast cancer patients. Anticancer Res 13(5c): 1895, 1994.
23. Seshadri R, Horsfall DJ, Firgaira F, Mc Caul K, Setlur V, Chalmers AH, Yeo R, Ingram D, Dawkins and Hahnel R: The relative prognostic significance of total cathepsin D and HER-2/neu oncogene amplification in breast cancer. The South Australian Breast Cancer Study Group. Int J Cancer 56(1): 61, 1994.
24. Foekins JA, Putten WL, Portengen H, Koning H, Thirion B, Figusch J and Klijin J: Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: Multivariate Analysis. J Clin Oncology 11(5): 899, 1993.
25. Hahnel R, Harvey J, Robbins P and Sterrett G: Cathepsin D in human breast cancer: Correlation with vascular invasion and other clinical and histopathological characteristics. Anticancer Res 13(6A): 2131, 1994.
26. Ruddle NH: Lymphotoxin production in AIDS. Immunol Today 7: 8, 1986.
27. Balkwill F, Bruke F, Talbot D, Tavernier J, Osborne R, Naylor S, Durbin H and Fiers W: Evidence for tumor necrosis factor/cachectin production in cancer. Lancet II, 1229, 1987.